CXCR1 and chronic obstructive pulmonary disease: However, another study using SCH527123 (MK-7123, Navarixin), a CXCR1/2 antagonist, was also attempted in chronic obstructive pulmonary disease (COPD) but was abandoned because of a severe decline in neutrophil number (Rennard et al., 2015).